Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 18.5% in December

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 108,500 shares, a drop of 18.5% from the December 15th total of 133,100 shares. Currently, 7.9% of the company’s shares are sold short. Based on an average trading volume of 24,000 shares, the short-interest ratio is currently 4.5 days.

Alaunos Therapeutics Price Performance

TCRT traded up $0.05 during trading on Friday, hitting $1.78. The company’s stock had a trading volume of 18,974 shares, compared to its average volume of 24,775. Alaunos Therapeutics has a twelve month low of $1.63 and a twelve month high of $32.85. The stock’s fifty day moving average price is $2.09 and its 200-day moving average price is $2.80.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.